This Article Full Text Full Text (PDF) All Versions of this Article: 90/9/5058    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dhindsa, S. Articles by Dandona, P. Search for Related Content PubMed PubMed Citation Articles by Dhindsa, S. Articles by Dandona, P. Related Collections Diabetes and Insulin Metabolism Obesity Lipid

Free Fatty Acid-Induced Insulin Resistance in the Obese Is Not Prevented by Rosiglitazone Treatment

Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, New York 14209

Address all correspondence and requests for reprints to: Paresh Dandona, B.Sc., M.B., B.S., D.Phil., F.R.C.P., Director, Diabetes-Endocrinology Center of Western New York, Distinguished Professor of Medicine and Pharmacology, Chief of Endocrinology, State University of New York at Buffalo, 3 Gates Circle, Buffalo, New York 14209. E-mail: pdandona{at}kaleidahealth.org.

Objective: Elevation of free fatty acids (FFAs) by the infusion of triglyceride-heparin emulsion infusion (TG-Hep) causes insulin resistance (IR). We examined the effect of insulin sensitizer (rosiglitazone) on FFA-induced IR.

Design: Nine obese subjects underwent a 6-h infusion of TG-Hep before and after 6 wk of rosiglitazone (8 mg/d) treatment. Hyperinsulinemic euglycemic clamps were performed during 0–2 and 4–6 h of TG-Hep.

Results: After rosiglitazone for 6 wk, fasting FFA concentration fell, but not significantly (489 ± 63 at 0 wk; 397 ± 58 µmol/liter at 6 wk; P = 0.16), whereas C-reactive protein (4.26 ± 0.95 at 0 wk; 2.03 ± 0.45 µg/ml at 6 wk) and serum amyloid A (17.36 ± 4.63 at 0 wk; 8.77 ± 1.63 µg/ml at 6 wk) decreased significantly. At 0 wk, TG-Hep infusion caused a decrease in glucose infusion rate (GIR) from 4.49 ± 0.95 mg/kg·min to 3.02 ± 0.59 mg/kg·min (P = 0.018). Rosiglitazone treatment resulted in an increase in baseline GIR to 6.29 ± 0.81 mg/kg·min (P = 0.03 vs. 0 wk), which decreased to 4.52 ± 0.53 mg/kg·min (P = 0.001) after 6 h of TG-Hep infusion. The decrease in GIR induced by TG-Hep infusion was similar before and after rosiglitazone therapy [1.47 ± 0.50 vs. 1.77 0.3 mg/kg·min (28.9 ± 6.5 vs. 26.4 ± 3.7%); P = 0.51]. The rise in FFAs and triglycerides after TG-Hep infusion was significantly lower at 6 wk (P = 0.006 for FFAs; P = 0.024 for triglycerides).

Conclusions: We conclude that rosiglitazone: 1) causes a significant increase in GIR; 2) induces a decrease in inflammatory mediators, C-reactive protein, and serum amyloid A; 3) decreases the rise in FFAs and triglycerides after TG-Hep infusion; and 4) does not prevent FFA-induced IR.

This article has been cited by other articles:

				W. L. Holland and S. A. Summers Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism Endocr. Rev., June 1, 2008; 29(4): 381 - 402. [Abstract] [Full Text] [PDF]

				F. Mittermayer, G. Schaller, J. Pleiner, K. Krzyzanowska, S. Kapiotis, M. Roden, and M. Wolzt Rosiglitazone Prevents Free Fatty Acid-Induced Vascular Endothelial Dysfunction J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2574 - 2580. [Abstract] [Full Text] [PDF]

				S. J. Lessard, D. A. Rivas, Z.-P. Chen, A. Bonen, M. A. Febbraio, D. W. Reeder, B. E. Kemp, B. B. Yaspelkis III, and J. A. Hawley Tissue-Specific Effects of Rosiglitazone and Exercise in the Treatment of Lipid-Induced Insulin Resistance Diabetes, July 1, 2007; 56(7): 1856 - 1864. [Abstract] [Full Text] [PDF]

				M. J. Serlie, G. Allick, J. E. Groener, M. T. Ackermans, R. Heijligenberg, B. C. Voermans, J. M. Aerts, A. J. Meijer, and H. P. Sauerwein Chronic Treatment with Pioglitazone Does Not Protect Obese Patients with Diabetes Mellitus Type II from Free Fatty Acid-Induced Insulin Resistance J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 166 - 171. [Abstract] [Full Text] [PDF]

				D. G. Haider, F. Mittermayer, G. Schaller, M. Artwohl, S. M. Baumgartner-Parzer, G. Prager, M. Roden, and M. Wolzt Free fatty acids normalize a rosiglitazone-induced visfatin release Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E885 - E890. [Abstract] [Full Text] [PDF]

				H. Ghanim, S. Dhindsa, A. Aljada, A. Chaudhuri, P. Viswanathan, and P. Dandona Low-Dose Rosiglitazone Exerts an Antiinflammatory Effect with an Increase in Adiponectin Independently of Free Fatty Acid Fall and Insulin Sensitization in Obese Type 2 Diabetics J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3553 - 3558. [Abstract] [Full Text] [PDF]

				C. R. Benton, D. P. Y. Koonen, J. Calles-Escandon, N. N. Tandon, J. F. C. Glatz, J. J. F. P. Luiken, J. J. Heikkila, and A. Bonen Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle J. Physiol., May 15, 2006; 573(1): 199 - 210. [Abstract] [Full Text] [PDF]